After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.

After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.

Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.